AVIR
Atea Pharmaceuticals, Inc.
Price Chart
No historical data available
Latest Quote
$4.71
-0.15 (-3.09%)
Current Price
| Previous Close | $4.86 |
| Open | $4.88 |
| Day High | $4.92 |
| Day Low | $4.70 |
| Volume | 91,712 |
Stock Information
| Shares Outstanding | 80.03M |
| Total Debt | $634K |
| Cash Equivalents | $256.01M |
| Net Income | $-169.52M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $376.93M |
| EPS (TTM) | $-2.11 |
| Exchange | NMS |
Recent Price History
No history data available. Data will be fetched automatically.
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
đ° Latest News
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2026-06-18T16:00:02Z
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Zacks âĸ 2026-06-09T13:40:03Z
Spotlight On Atea Pharmaceuticals And 2 Other Prominent Penny Stocks
Simply Wall St. âĸ 2026-05-25T12:05:26Z
Here's Why We're Watching Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation
Simply Wall St. âĸ 2026-05-19T12:46:08Z
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
Zacks âĸ 2026-05-15T13:35:02Z
Atea Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-13T12:30:00Z
Atea Pharmaceuticals Inc (AVIR) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...
GuruFocus.com âĸ 2026-05-13T05:01:38ZAtea Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-12T22:08:10Z
Atea Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-06T13:30:00Z
Atea Pharmaceuticals Inc (AVIR) Q4 2025 Earnings Call Highlights: Advancing HCV Treatments and ...
GuruFocus.com âĸ 2026-03-06T05:02:31Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $180,887,000 | $192,950,000 | $164,162,000 | $130,650,000 |
| Net Non Operating Interest Income Expense | $16,376,000 | $25,490,000 | $29,224,000 | $11,151,000 |
| Operating Expense | $180,887,000 | $192,950,000 | $164,162,000 | $130,650,000 |
| General And Administrative Expense | $32,863,000 | $48,849,000 | $49,919,000 | $48,714,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-158,349,000 | $-168,385,000 | $-135,956,000 | $-115,909,000 |
| Net Interest Income | $16,376,000 | $25,490,000 | $29,224,000 | $11,151,000 |
| Interest Income | $16,376,000 | $25,490,000 | $29,224,000 | $11,151,000 |
| Normalized Income | $-158,349,000 | $-168,385,000 | $-135,956,000 | $-115,909,000 |
| Net Income From Continuing And Discontinued Operation | $-158,349,000 | $-168,385,000 | $-135,956,000 | $-115,909,000 |
| Total Operating Income As Reported | $-180,887,000 | $-192,950,000 | $-164,162,000 | $-130,650,000 |
| Net Income Common Stockholders | $-158,349,000 | $-168,385,000 | $-135,956,000 | $-115,909,000 |
| Net Income | $-158,349,000 | $-168,385,000 | $-135,956,000 | $-115,909,000 |
| Net Income Including Noncontrolling Interests | $-158,349,000 | $-168,385,000 | $-135,956,000 | $-115,909,000 |
| Net Income Continuous Operations | $-158,349,000 | $-168,385,000 | $-135,956,000 | $-115,909,000 |
| Pretax Income | $-164,511,000 | $-167,460,000 | $-134,938,000 | $-119,499,000 |
| Interest Income Non Operating | $16,376,000 | $25,490,000 | $29,224,000 | $11,151,000 |
| Operating Income | $-180,887,000 | $-192,950,000 | $-164,162,000 | $-130,650,000 |
| Per Share | ||||
| Diluted EPS | $-1.94 | $-2.00 | $-1.63 | $-1.39 |
| Basic EPS | $-1.94 | $-2.00 | $-1.63 | $-1.39 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-180,471,000 | $-192,534,000 | $-163,746,000 | $-130,390,000 |
| Reconciled Depreciation | $416,000 | $416,000 | $416,000 | $260,000 |
| EBITDA (Bullshit earnings) | $-180,471,000 | $-192,534,000 | $-163,746,000 | $-130,390,000 |
| EBIT | $-180,887,000 | $-192,950,000 | $-164,162,000 | $-130,650,000 |
| Diluted Average Shares | $81,495,352 | $84,264,715 | $83,389,750 | $83,245,385 |
| Basic Average Shares | $81,495,352 | $84,264,715 | $83,389,750 | $83,245,385 |
| Diluted NI Availto Com Stockholders | $-158,349,000 | $-168,385,000 | $-135,956,000 | $-115,909,000 |
| Tax Provision | $-6,162,000 | $925,000 | $1,018,000 | $-3,590,000 |
| Research And Development | $148,024,000 | $144,101,000 | $114,243,000 | $81,936,000 |
| Selling General And Administration | $32,863,000 | $48,849,000 | $49,919,000 | $48,714,000 |
| Other Gand A | $32,863,000 | $48,849,000 | $49,919,000 | $48,714,000 |
Fetched: 2026-07-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $275,434,000 | $438,867,000 | $555,192,000 | $640,572,000 |
| Total Assets | $315,218,000 | $464,668,000 | $594,968,000 | $666,708,000 |
| Total Non Current Assets | $4,227,000 | $2,313,000 | $4,513,000 | $5,786,000 |
| Other Non Current Assets | $3,136,000 | $197,000 | $1,396,000 | $1,692,000 |
| Current Assets | $310,991,000 | $462,355,000 | $590,455,000 | $660,922,000 |
| Other Current Assets | $9,161,000 | $7,634,000 | $12,349,000 | $14,213,000 |
| Cash Cash Equivalents And Short Term Investments | $301,830,000 | $454,721,000 | $578,106,000 | $646,709,000 |
| Cash And Cash Equivalents | $95,713,000 | $64,696,000 | $143,823,000 | $188,460,000 |
| Non Current Prepaid Assets | - | - | - | $1,494,000 |
| Prepaid Assets | - | - | - | - |
| Receivables | - | - | - | - |
| Debt | ||||
| Total Debt | $843,000 | $1,642,000 | $2,402,000 | $3,124,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $842,000 | $1,642,000 | $2,403,000 |
| Current Debt And Capital Lease Obligation | $843,000 | $800,000 | $760,000 | $721,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $39,784,000 | $25,801,000 | $39,776,000 | $26,136,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $7,198,000 | $7,400,000 | $7,658,000 |
| Tradeand Other Payables Non Current | $0 | $6,356,000 | $5,758,000 | $5,255,000 |
| Current Liabilities | $39,784,000 | $18,603,000 | $32,376,000 | $18,478,000 |
| Payables And Accrued Expenses | $38,941,000 | $17,803,000 | $31,616,000 | $17,757,000 |
| Payables | $12,945,000 | $4,458,000 | $4,252,000 | $2,650,000 |
| Accounts Payable | $12,945,000 | $4,458,000 | $4,252,000 | $2,551,000 |
| Total Tax Payable | - | - | $0 | $99,000 |
| Income Tax Payable | - | - | $0 | $99,000 |
| Other Non Current Liabilities | - | - | - | - |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $275,434,000 | $438,867,000 | $555,192,000 | $640,572,000 |
| Total Equity Gross Minority Interest | $275,434,000 | $438,867,000 | $555,192,000 | $640,572,000 |
| Stockholders Equity | $275,434,000 | $438,867,000 | $555,192,000 | $640,572,000 |
| Gains Losses Not Affecting Retained Earnings | $174,000 | $233,000 | $207,000 | $-684,000 |
| Other Equity Adjustments | $174,000 | $233,000 | $207,000 | $-684,000 |
| Retained Earnings | $-522,569,000 | $-364,220,000 | $-195,835,000 | $-59,879,000 |
| Other | ||||
| Ordinary Shares Number | $78,126,796 | $84,463,059 | $83,435,513 | $83,287,639 |
| Share Issued | $78,126,796 | $84,463,059 | $83,435,513 | $83,287,639 |
| Tangible Book Value | $275,434,000 | $438,867,000 | $555,192,000 | $640,572,000 |
| Invested Capital | $275,434,000 | $438,867,000 | $555,192,000 | $640,572,000 |
| Working Capital | $271,207,000 | $443,752,000 | $558,079,000 | $642,444,000 |
| Capital Lease Obligations | $843,000 | $1,642,000 | $2,402,000 | $3,124,000 |
| Total Capitalization | $275,434,000 | $438,867,000 | $555,192,000 | $640,572,000 |
| Additional Paid In Capital | $797,751,000 | $802,770,000 | $750,737,000 | $701,052,000 |
| Capital Stock | $78,000 | $84,000 | $83,000 | $83,000 |
| Common Stock | $78,000 | $84,000 | $83,000 | $83,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $842,000 | $1,642,000 | $2,403,000 |
| Current Capital Lease Obligation | $843,000 | $800,000 | $760,000 | $721,000 |
| Current Accrued Expenses | $25,996,000 | $13,345,000 | $27,364,000 | $15,107,000 |
| Net PPE | $1,091,000 | $2,116,000 | $3,117,000 | $4,094,000 |
| Accumulated Depreciation | $-1,521,000 | $-1,105,000 | $-689,000 | $-273,000 |
| Gross PPE | $2,612,000 | $3,221,000 | $3,806,000 | $4,367,000 |
| Leases | $1,475,000 | $1,475,000 | $1,475,000 | $1,475,000 |
| Other Properties | $639,000 | $1,248,000 | $1,833,000 | $2,394,000 |
| Machinery Furniture Equipment | $498,000 | $498,000 | $498,000 | $498,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $206,117,000 | $390,025,000 | $434,283,000 | $458,249,000 |
| Current Deferred Revenue | - | - | - | - |
Fetched: 2026-07-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-132,031,000 | $-135,499,000 | $-85,395,000 | $-122,925,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-132,031,000 | $-135,499,000 | $-85,395,000 | $-120,982,000 |
| Cash Flow From Continuing Operating Activities | $-132,031,000 | $-135,499,000 | $-85,395,000 | $-120,982,000 |
| Investing Activities | ||||
| Investing Cash Flow | $188,793,000 | $56,105,000 | $40,303,000 | $-455,410,000 |
| Cash Flow From Continuing Investing Activities | $188,793,000 | $56,105,000 | $40,303,000 | $-455,410,000 |
| Capital Expenditure | - | - | - | $-1,943,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-25,519,000 | $0 | - | - |
| Issuance Of Capital Stock | $58,000 | $0 | - | $230,000 |
| Financing Cash Flow | $-25,745,000 | $267,000 | $257,000 | $370,000 |
| Cash Flow From Continuing Financing Activities | $-25,745,000 | $267,000 | $257,000 | $370,000 |
| Net Other Financing Charges | $-485,000 | - | - | - |
| Net Common Stock Issuance | $-25,461,000 | $0 | - | $230,000 |
| Common Stock Issuance | $58,000 | $0 | - | $230,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $95,713,000 | $64,696,000 | $143,823,000 | $188,658,000 |
| Beginning Cash Position | $64,696,000 | $143,823,000 | $188,658,000 | $764,680,000 |
| Changes In Cash | $31,017,000 | $-79,127,000 | $-44,835,000 | $-576,022,000 |
| Proceeds From Stock Option Exercised | $201,000 | $267,000 | $257,000 | $370,000 |
| Common Stock Payments | $-25,519,000 | $0 | - | - |
| Net Investment Purchase And Sale | $188,793,000 | $56,105,000 | $40,303,000 | $-453,467,000 |
| Sale Of Investment | $470,732,000 | $517,282,000 | $602,665,000 | $91,885,000 |
| Purchase Of Investment | $-281,939,000 | $-461,177,000 | $-562,362,000 | $-545,352,000 |
| Change In Working Capital | $16,482,000 | $-7,476,000 | $16,163,000 | $-46,586,000 |
| Change In Other Current Liabilities | $-190,000 | $-175,000 | $-161,000 | $765,000 |
| Change In Other Current Assets | $-2,939,000 | $0 | $98,000 | $-1,494,000 |
| Change In Payables And Accrued Expense | $21,138,000 | $-13,215,000 | $14,362,000 | $-39,606,000 |
| Change In Accrued Expense | $12,651,000 | $-13,421,000 | $12,661,000 | $-37,623,000 |
| Change In Payable | $8,487,000 | $206,000 | $1,701,000 | $-1,983,000 |
| Change In Account Payable | $8,487,000 | $206,000 | $1,701,000 | $-1,983,000 |
| Change In Prepaid Assets | $-1,527,000 | $5,914,000 | $1,864,000 | $-6,251,000 |
| Stock Based Compensation | $20,720,000 | $51,767,000 | $49,428,000 | $46,718,000 |
| Amortization Of Securities | $-4,944,000 | $-11,821,000 | $-15,446,000 | $-5,465,000 |
| Deferred Tax | $-6,356,000 | $0 | - | - |
| Deferred Income Tax | $-6,356,000 | $0 | - | - |
| Depreciation Amortization Depletion | $416,000 | $416,000 | $416,000 | $260,000 |
| Depreciation And Amortization | $416,000 | $416,000 | $416,000 | $260,000 |
| Net Income From Continuing Operations | $-158,349,000 | $-168,385,000 | $-135,956,000 | $-115,909,000 |
| Net PPE Purchase And Sale | - | - | $0 | $-1,943,000 |
| Purchase Of PPE | - | - | $0 | $-1,943,000 |
| Change In Receivables | - | - | - | $0 |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-07-16